Druck Icon
 

Eckert & Ziegler Acquires Property for Radiopharmaceutical Production Site in China

Berlin, 5 November 2021. Eckert & Ziegler AG (ISIN DE0005659700), a global specialist for isotope applications in medicine and industry has acquired an approximately 7,000 m² property with an expansion option for the building of its Chinese production facility in Jintan (PR China). The purchase was made through a public tender process. The location in the Jiangsu province near Shanghai will be used to build production facilities for radiopharmaceuticals and radioisotopes as well as Eckert & Ziegler's administrative headquarters for the Chinese market. In the medium term, other divisions of the Eckert & Ziegler Group as well as service facilities are also to be located there and third parties are to be offered the infrastructure for joint use. The business in China is managed by the wholly owned subsidiary Qi Kang Medical Technology (Changzhou) Co., Ltd. (QKM).

Construction will start at the beginning of next year. Completion of the building and operational readiness are to take place in stages. By end 2027, the investment volume, including land, building, technical equipment, and intangible assets, will amount to up to 50 million EUR. If the project can be implemented as planned, radiopharmaceutical contract production for the international pharmaceutical industry as well as the sale of the company's own products will take place at the new site in Jintan. Eckert & Ziegler will thus also offer a one-stop service in Asia for a wide range of radiopharmaceutical services under "GMP and cGMP conditions".

"Cancer is one of the most common causes of death in China," explained Dr. Andreas Eckert, founder and CEO of Eckert & Ziegler. "Treatment methods based on precision oncology should also be available to patients in China in the future. As a globally active supplier for oncology specialty companies, it is important for us to be represented in China with a licensed production site and a strong local team. With the property acquisition in Jintan, we are well prepared for the expected growth in China."

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com



 


 

 

 

show this